First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Part 1 (Phase IA single agent portion) will test the tolerability of continuous twice a day
dosing of GRN-300, a salt-inducible kinase inhibitor, with each cycle consisting of 28 days
of treatment. The number of administered cycles will depend on the tolerability of each dose
level and the severity and occurrence of side effects and DLTs.
Part 2 (Phase IB combination therapy portion) will test the tolerability of continuous 28-day
cycles of GRN-300 in combination with weekly paclitaxel x 3.
Overall duration of the study will be approximately 24 months, depending on the rate of
enrollment and number of subjects enrolled.
Overall duration of the study will be approximately 24 months, depending on the rate of
enrollment and number of subjects enrolled.